Biovest International Inc.

Biovest International, Inc. has announced that it conducted a formal clinical guidance meeting with the U.S. Food and Drug Administration (FDA) to determine the most expeditious U.S. registration pathway for BiovaxID™, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin’s lymphoma that is manufactured in Coon Rapids.

facebook icon
twitter icon
comments icon
up arrow
up arrow